<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923191</url>
  </required_header>
  <id_info>
    <org_study_id>NUIG-2021-001</org_study_id>
    <nct_id>NCT04923191</nct_id>
  </id_info>
  <brief_title>The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent</brief_title>
  <acronym>PIONEER-IV</acronym>
  <official_title>Non-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated With Unrestricted Use of the Healing-Targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy After 1-month of Dual-antiplatelet Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Ireland, Galway, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Ireland, Galway, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled,&#xD;
      multi-center study comparing clinical outcomes between angiography-derived physiology&#xD;
      guidance to LRDP and usual care in an all-comers patient population (including patients with&#xD;
      high bleeding risk, HBR) undergoing PCI with unrestrictive use of the HT Supreme&#xD;
      sirolimus-eluting stent. Patients will be randomized to either angio-based physiology&#xD;
      guidance (QFR) or local routine diagnostic procedure (LRDP) and usual care. Patients will be&#xD;
      treated with 1-year P2Y12 inhibitor monotherapy after 1-month of dual-antiplatelet therapy in&#xD;
      approximately 2540 (2*1270) patients. All patients (both cohorts) must receive dual&#xD;
      anti-platelet therapy, being aspirin (ASA) and ticagrelor for 1 month, followed by 11 months&#xD;
      of ticagrelor only (i.e. monotherapy). At 1 year, ticagrelor monotherapy is replaced by&#xD;
      aspirin monotherapy or left to the discretion of the operator.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-oriented Composite Endpoint (PoCE)</measure>
    <time_frame>12 months</time_frame>
    <description>PoCE is a composite clinical endpoint of:&#xD;
all-cause death;&#xD;
any stroke, Modified Rankin scale, (MRS ≥1);&#xD;
any myocardial infarction;&#xD;
any clinically and physiologically driven revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vessel-oriented composite endpoints (VoCE)</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>VoCE is a composite clinical endpoint of:&#xD;
Vessel-related cardiovascular Death&#xD;
Target-vessel related MI&#xD;
Clinically and physiologically-oriented Target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-oriented composite endpoint (DoCE)</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>DoCE is a composite endpoint of:&#xD;
Cardiovascular Death&#xD;
Target-vessel related MI&#xD;
Clinically and physiologically-oriented Target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI)</measure>
    <time_frame>48 hours post-procedure</time_frame>
    <description>Peri-procedure Myocardial Infarction according to 4th universal definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success Rate</measure>
    <time_frame>index procedure</time_frame>
    <description>according to the statement from European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>Procedure, 12, 24 and 36 months</time_frame>
    <description>Definite, Probable, Definite or Probable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>TVF is a composite of:&#xD;
Cardiovascular Death&#xD;
Target-vessel related MI&#xD;
Clinically and physiologically-oriented Target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12, 24 and 36 months follow-up</time_frame>
    <description>Bleeding according to Bleeding Academic Research Consortium (BARC) (BARC 2, 3 and 5) classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2540</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Angiography-derived Physiology Guidance (Quantitative Flow Ratio, QFR)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Local routine diagnostic procedure (LRDP) and usual care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care</intervention_name>
    <description>percutaneous coronary intervention</description>
    <arm_group_label>Angiography-derived Physiology Guidance (Quantitative Flow Ratio, QFR)</arm_group_label>
    <arm_group_label>Local routine diagnostic procedure (LRDP) and usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has chronic stable angina, acute coronary syndromes or silent ischemia;&#xD;
&#xD;
          -  Presence of one or more coronary artery stenoses of ≥50% (by visual assessment) in a&#xD;
             native coronary artery (with or without prior stent/other device treatment) or in a&#xD;
             saphenous venous or arterial bypass conduit suitable for coronary stent implantation;&#xD;
&#xD;
          -  The vessel should have a reference vessel diameter of at least 2.25 mm by visual&#xD;
             assessment (no limitation on the number of treated lesions, vessels, or lesion&#xD;
             length);&#xD;
&#xD;
          -  Patient has been informed of the nature of the study and agrees to its provisions and&#xD;
             has provided written informed consent as approved by the Ethical Committee and is&#xD;
             willing to comply with all protocol-required (follow-up) evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed&#xD;
             within 7 days prior to the index procedure in women of child-bearing potential&#xD;
             according to local practice);&#xD;
&#xD;
          2. Known intolerance to cobalt chromium, and medications such as sirolimus, aspirin,&#xD;
             heparin, bivalirudin or P2Y12 inhibitors;&#xD;
&#xD;
          3. Planned major elective surgery requiring discontinuation of (dual)anti platelet&#xD;
             therapy (DAPT) within 12 months of procedure;&#xD;
&#xD;
          4. Concurrent medical condition with a life expectancy of less than 3 years;&#xD;
&#xD;
          5. Currently participating in another trial and not yet at its primary endpoint;&#xD;
&#xD;
          6. Active pathological bleeding;&#xD;
&#xD;
          7. History of intracranial haemorrhage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick W Serruys, MD</last_name>
    <phone>+31622924061</phone>
    <email>Patrick.Serruys@Nuigalway.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoshinobu Onuma, MD</last_name>
    <phone>+353852882318</phone>
    <email>Yoshinobu.Onuma@Nuigalway.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National University of Ireland</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <contact>
      <last_name>Faisal Sharif, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Smits, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Javier Escaned, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreas Baumbach, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Ireland, Galway, Ireland</investigator_affiliation>
    <investigator_full_name>Patrick Serruys</investigator_full_name>
    <investigator_title>Professor of Interventional Cardiology &amp; Innovation at the National University of Ireland, Galway, Ireland</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>ischemia</keyword>
  <keyword>quantitative flow ratio (QFR)</keyword>
  <keyword>P2Y12 monotherapy</keyword>
  <keyword>drug-eluting stent</keyword>
  <keyword>physiology guidance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

